

Alice Panchaud

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/519753/publications.pdf>

Version: 2024-02-01

82
papers

2,842
citations

186265

28
h-index

189892

50
g-index

86
all docs

86
docs citations

86
times ranked

3783
citing authors

#	ARTICLE	IF	CITATIONS
1	Antihistamine use during breastfeeding with focus on breast milk transfer and safety in humans: A systematic literature review. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2022, 130, 171-181.	2.5	11
2	Use of Prescribed Drugs to Treat Chronic Diseases during Pregnancy in Outpatient Care in Switzerland between 2014 and 2018: Descriptive Analysis of Swiss Health Care Claims Data. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 1456.	2.6	4
3	Self-Reported Medication Use among Pregnant and Breastfeeding Women during the COVID-19 Pandemic: A Cross-Sectional Study in Five European Countries. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 1389.	2.6	16
4	Self-Reported Medication Use among Pregnant and Postpartum Women during the Third Wave of the COVID-19 Pandemic: A European Multinational Cross-Sectional Study. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 5335.	2.6	14
5	Comment to "Pregnancy and COVID-19, focus on vaccine and pharmacological treatment". <i>Journal of Reproductive Immunology</i> , 2022, 152, 103639.	1.9	0
6	COVID-19 mRNA vaccine in pregnancy: Results of the Swiss COVI-PREG registry, an observational prospective cohort study. <i>Lancet Regional Health - Europe</i> , The, 2022, 18, 100410.	5.6	20
7	Protocol for a sequential, prospective meta-analysis to describe coronavirus disease 2019 (COVID-19) in the pregnancy and postpartum periods. <i>PLoS ONE</i> , 2022, 17, e0270150.	2.5	3
8	Recording of Chronic Diseases and Adverse Obstetric Outcomes during Hospitalizations for a Delivery in the National Swiss Hospital Medical Statistics Dataset between 2012 and 2018: An Observational Cross-Sectional Study. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 7922.	2.6	0
9	Pregnancy outcome following first-trimester exposure to fingolimod: A collaborative ENTIS study. <i>Multiple Sclerosis Journal</i> , 2021, 27, 475-478.	3.0	16
10	Mental health status of pregnant and breastfeeding women during the COVID-19 pandemic: A multinational cross-sectional study. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2021, 100, 1219-1229.	2.8	140
11	Valproate in pregnancy: authors' reply. <i>Swiss Medical Weekly</i> , 2021, 151, w20481.	1.6	0
12	Prolonged Maternal Zika Viremia as a Marker of Adverse Perinatal Outcomes. <i>Emerging Infectious Diseases</i> , 2021, 27, 490-498.	4.3	11
13	Maternal Infection and Adverse Pregnancy Outcomes among Pregnant Travellers: Results of the International Zika Virus in Pregnancy Registry. <i>Viruses</i> , 2021, 13, 341.	3.3	1
14	Vaccine Willingness and Impact of the COVID-19 Pandemic on Women's Perinatal Experiences and Practices: A Multinational, Cross-Sectional Study Covering the First Wave of the Pandemic. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 3367.	2.6	83
15	Clinical and economic impacts of explicit tools detecting prescribing errors: A systematic review. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021, 46, 877-886.	1.5	7
16	A comprehensive review on non-clinical methods to study transfer of medication into breast milk: A contribution from the ConcePTION project. <i>Biomedicine and Pharmacotherapy</i> , 2021, 136, 111038.	5.6	19
17	Exposure to alirocumab during the first trimester of pregnancy: A case report. <i>Birth Defects Research</i> , 2021, 113, 1156-1160.	1.5	5
18	SARS-CoV-2 Vaccine Willingness among Pregnant and Breastfeeding Women during the First Pandemic Wave: A Cross-Sectional Study in Switzerland. <i>Viruses</i> , 2021, 13, 1199.	3.3	54

#	ARTICLE	IF	CITATIONS
19	Ability to detect potentially inappropriate prescribing in older patients: comparative analysis between PIM-Check and STOPP/STARTv2. <i>European Journal of Clinical Pharmacology</i> , 2021, 77, 1747-1756.	1.9	4
20	Association between confirmed congenital Zika infection at birth and outcomes up to 3 years of life. <i>Nature Communications</i> , 2021, 12, 3270.	12.8	21
21	Maternal outcomes and risk factors for COVID-19 severity among pregnant women. <i>Scientific Reports</i> , 2021, 11, 13898.	3.3	77
22	A review of the evidence on the risk of congenital malformations and neurodevelopmental disorders in association with antiseizure medications during pregnancy. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 1-13.	2.4	5
23	Current Data on COVID-19 mRNA-Vaccine Safety during Pregnancy Might Be Subject to Selection Bias. Reply to Stroobandt, S.; Stroobandt, R. Data of the COVID-19 mRNA-Vaccine V-Safe Surveillance System and Pregnancy Registry Reveals Poor Embryonic and Second Trimester Fetal Survival Rate. Comment on Stuckelberger et al. SARS-CoV-2 Vaccine Willingness among Pregnant and Breastfeeding Women during the First Pandemic Wave: A Cross-Sectional Study in Switzerland. <i>Viruses</i> 2021, 13, 1199.	3.3	3
24	Use of valproate in pregnancy and in women of childbearing age between 2014 and 2018 in Switzerland: a retrospective analysis of Swiss healthcare claims data. <i>Swiss Medical Weekly</i> , 2021, 151, w20386.	1.6	8
25	Impact of Pharmaceutical Interventions in Hospitalized Patients: A Comparative Study Between Clinical Pharmacists and an Explicit Criteria-Based Tool. <i>Current Therapeutic Research</i> , 2021, 95, 100650.	1.2	4
26	Use of drugs to treat symptoms and acute conditions during pregnancy in outpatient care in Switzerland between 2014 and 2018: analysis of Swiss healthcare claims data. <i>Swiss Medical Weekly</i> , 2021, 151, w30048.	1.6	11
27	Placental infection by Zika virus in French Guiana. <i>Ultrasound in Obstetrics and Gynecology</i> , 2020, 56, 740-748.	1.7	19
28	An international registry for emergent pathogens and pregnancy. <i>Lancet</i> , 2020, 395, 1483-1484.	13.7	32
29	Zika Virus. <i>Pathogens</i> , 2020, 9, 898.	2.8	54
30	Tachysystole and risk of cesarean section after labor induction using misoprostol: A cohort study. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2020, 249, 54-58.	1.1	1
31	SARS-CoV-2 in the context of past coronaviruses epidemics: Consideration for prenatal care. <i>Prenatal Diagnosis</i> , 2020, 40, 1641-1654.	2.3	22
32	Association Between Mode of Delivery Among Pregnant Women With COVID-19 and Maternal and Neonatal Outcomes in Spain. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 296.	7.4	120
33	A population pharmacokinetic model for escitalopram and its major metabolite in depressive patients during the perinatal period: Prediction of infant drug exposure through breast milk. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1642-1653.	2.4	13
34	Vertical transmission and materno-fetal outcomes in 13 patients with coronavirus disease 2019. <i>Clinical Microbiology and Infection</i> , 2020, 26, 1585-1587.	6.0	9
35	Should we stop aspirin prophylaxis in pregnant women diagnosed with COVID-19?. <i>Ultrasound in Obstetrics and Gynecology</i> , 2020, 55, 843-844.	1.7	20
36	Beta-blocker use and up-titration after acute ST-segment elevation myocardial infarction: a cohort study. <i>Swiss Medical Weekly</i> , 2020, 150, w20321.	1.6	0

#	ARTICLE	IF	CITATIONS
37	Identifying pregnancies in insurance claims data: Methods and application to retinoid teratogenic surveillance. <i>Pharmacoepidemiology and Drug Safety</i> , 2019, 28, 1211-1221.	1.9	51
38	A critical analysis of the neurodevelopmental and neurosensory outcomes after 2 years for children with in utero Zika virus exposure. <i>Nature Medicine</i> , 2019, 25, 1641-1642.	30.7	8
39	Risk-benefit balance assessment of SSRI antidepressant use during pregnancy and lactation based on best available evidence – an update. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 949-963.	2.4	47
40	Zika virus during pregnancy: From maternal exposure to congenital Zika virus syndrome. <i>Prenatal Diagnosis</i> , 2019, 39, 420-430.	2.3	54
41	Infant Exposure to Methylphenidate and Duloxetine During Lactation. <i>Breastfeeding Medicine</i> , 2018, 13, 221-225.	1.7	4
42	Pregnancy outcomes in women on metformin for diabetes or other indications among those seeking teratology information services. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 568-578.	2.4	35
43	Maternal-fetal transmission and adverse perinatal outcomes in pregnant women infected with Zika virus: prospective cohort study in French Guiana. <i>BMJ: British Medical Journal</i> , 2018, 363, k4431.	2.3	106
44	Self-reported perinatal depressive symptoms and postnatal symptom severity after treatment with antidepressants in pregnancy: a cross-sectional study across 12 European countries using the Edinburgh Postnatal Depression Scale. <i>Clinical Epidemiology</i> , 2018, Volume 10, 655-669.	3.0	20
45	Anticonvulsants and the risk of perinatal bleeding complications. <i>Neurology</i> , 2018, 91, e533-e542.	1.1	4
46	Zika virus, vaccines, and antiviral strategies. <i>Expert Review of Anti-Infective Therapy</i> , 2018, 16, 471-483.	4.4	19
47	Zika virus: are we going too far?. <i>Lancet, The</i> , 2017, 389, 151.	13.7	5
48	Simultaneous determination of selective serotonin reuptake inhibitors and their main metabolites in human breast milk by liquid chromatography-electrospray mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2017, 1057, 101-109.	2.3	19
49	Pregabalin use early in pregnancy and the risk of major congenital malformations. <i>Neurology</i> , 2017, 88, 2020-2025.	1.1	56
50	Use of atypical antipsychotics in pregnancy and maternal gestational diabetes. <i>Journal of Psychiatric Research</i> , 2017, 95, 84-90.	3.1	24
51	Outbreak in meldonium positive laboratory tests: are we missing something?. <i>British Journal of Sports Medicine</i> , 2016, 50, 1422-1423.	6.7	4
52	Population pharmacokinetic analysis of elvitegravir and cobicistat in HIV-1-infected individuals. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1933-1942.	3.0	13
53	Pregnancy outcome following maternal exposure to pregabalin may call for concern. <i>Neurology</i> , 2016, 86, 2251-2257.	1.1	75
54	Clinical management of pregnant women exposed to Zika virus. <i>Lancet Infectious Diseases, The</i> , 2016, 16, 523.	9.1	35

#	ARTICLE	IF	CITATIONS
55	Stereoselective determination of citalopram and desmethylcitalopram in human plasma and breast milk by liquid chromatography tandem mass spectrometry. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016, 131, 233-245.	2.8	16
56	An international registry for women exposed to Zika virus during pregnancy: time for answers. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 995-996.	9.1	12
57	Antipsychotic Use in Pregnancy and the Risk for Congenital Malformations. <i>JAMA Psychiatry</i> , 2016, 73, 938.	11.0	206
58	Harness shared data in international Zika registry. <i>BMJ</i> , The, 2016, 355, i5319.	6.0	3
59	Emerging Role of Zika Virus in Adverse Fetal and Neonatal Outcomes. <i>Clinical Microbiology Reviews</i> , 2016, 29, 659-694.	13.6	133
60	Clinical management of pregnant women exposed to Zika virus. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 773.	9.1	12
61	Safety of Drugs during Pregnancy and Breastfeeding in Cystic Fibrosis Patients. <i>Respiration</i> , 2016, 91, 333-348.	2.6	11
62	Utility of an Algorithm to Increase the Accuracy of Medication History in an Obstetrical Setting. <i>PLoS ONE</i> , 2016, 11, e0151205.	2.5	1
63	Vitamin D Time Profile Based on the Contribution of Non-Genetic and Genetic Factors in HIV-Infected Individuals of European Ancestry. <i>Antiviral Therapy</i> , 2015, 20, 261-269.	1.0	5
64	Pregnancy Outcome Following Maternal Exposure to Mirtazapine. <i>Journal of Clinical Psychopharmacology</i> , 2015, 35, 250-259.	1.4	32
65	Risk-benefit balance assessment of SSRI antidepressant use during pregnancy and lactation based on best available evidence. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 413-427.	2.4	47
66	PATTERNS AND FACTORS ASSOCIATED WITH LOW ADHERENCE TO PSYCHOTROPIC MEDICATIONS DURING PREGNANCY-A CROSS-SECTIONAL, MULTINATIONAL WEB-BASED STUDY. <i>Depression and Anxiety</i> , 2015, 32, 426-436.	4.1	47
67	Pregnancy outcome following maternal exposure to pregabalin: a reason for concern? a collaborative entis and motherisk study. <i>Clinical Therapeutics</i> , 2015, 37, e1.	2.5	0
68	Medication use in pregnancy: a cross-sectional, multinational web-based study. <i>BMJ Open</i> , 2014, 4, e004365.	1.9	311
69	Population pharmacokinetic modelling and evaluation of different dosage regimens for darunavir and ritonavir in HIV-infected individuals. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2489-2498.	3.0	31
70	Risk perception by healthcare professionals related to drug use during pregnancy: a Swiss survey. <i>Swiss Medical Weekly</i> , 2014, 144, w13936.	1.6	20
71	Pregnancy outcome following maternal exposure to statins: a multicentre prospective study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2013, 120, 463-471.	2.3	94
72	Authors' response to: Statins in pregnancy: safety and perspectives of therapeutic applications. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2013, 120, 1440-1440.	2.3	1

#	ARTICLE	IF	CITATIONS
73	Pregnancy Outcomes Following Use of Escitalopram: A Prospective Comparative Cohort Study. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 766-770.	2.0	48
74	Management of Deficient Lactation in Switzerland and Canada: A Survey of Midwives' Current Practices. <i>Breastfeeding Medicine</i> , 2012, 7, 317-318.	1.7	15
75	Pregnancy Outcome Following Exposure to Topical Retinoids: A Multicenter Prospective Study. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 1844-1851.	2.0	48
76	Rates of Major Malformations in Infants Following Exposure to Duloxetine During Pregnancy. <i>Journal of Clinical Psychiatry</i> , 2012, 73, 1471.	2.2	27
77	Prediction of Infant Drug Exposure Through Breastfeeding: Population PK Modeling and Simulation of Fluoxetine Exposure. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 89, 830-836.	4.7	24
78	Is use of nifurtimox for the treatment of Chagas disease compatible with breast feeding? A population pharmacokinetics analysis. <i>Archives of Disease in Childhood</i> , 2010, 95, 224-228.	1.9	36
79	Evaluation of the Risk of Congenital Cardiovascular Defects Associated With Use of Paroxetine During Pregnancy. <i>American Journal of Psychiatry</i> , 2008, 165, 749-752.	7.2	164
80	Place des apports oraux en acides gras oméga-3 dans la mucoviscidose. <i>Nutrition Clinique Et Metabolisme</i> , 2006, 20, 41-47.	0.5	0
81	Biological effects of a dietary omega-3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: A randomized, crossover placebo-controlled trial. <i>Clinical Nutrition</i> , 2006, 25, 418-427.	5.0	72
82	A validated liquid chromatography-mass spectrometry method for the determination of leukotrienes B4 and B5 produced by stimulated human polymorphonuclear leukocytes. <i>Analytical Biochemistry</i> , 2005, 341, 58-68.	2.4	10